Literature DB >> 11917813

Newly described or emerging human species of nontuberculous mycobacteria.

Barbara A Brown-Elliott1, David E Griffith, Richard J Wallace.   

Abstract

The advent of molecular testing in the laboratory has brought about the recognition of multiple newly characterized mycobacterial species not previously recognizable with most standard techniques. Some of the species are nonpathogenic, but the majority may cause clinical disease. Each is likely to have its own biology, drug susceptibility pattern, and response to drug/surgical therapy. Thus, it is important to try to recognize these new species in the laboratory. A study of the phenotypic and genotypic characteristics of these new species also may help to elucidate the epidemiology and pathogenesis of these organisms. In addition, there are multiple emerging species of nontuberculous mycobacteria including M. ulcerans, M. haemophilum, M. xenopi, and M. malmoense. [table: see text] These species are being recognized increasingly as a cause of human disease and recovered within the laboratory. The clinician must learn about these new pathogens to recognize them clinically and assist the laboratory in their recovery.

Entities:  

Mesh:

Year:  2002        PMID: 11917813     DOI: 10.1016/s0891-5520(03)00052-7

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  16 in total

1.  Intrinsic macrolide resistance in rapidly growing mycobacteria.

Authors:  Kevin A Nash; Nadya Andini; Yansheng Zhang; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

2.  Comparison of DNA pyrosequencing with alternative methods for identification of mycobacteria.

Authors:  Loree C Heller; Michael Jones; Ray H Widen
Journal:  J Clin Microbiol       Date:  2008-04-16       Impact factor: 5.948

3.  Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.

Authors:  Kevin A Nash; Yansheng Zhang; Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Antimicrob Chemother       Date:  2004-12-08       Impact factor: 5.790

4.  IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB.

Authors:  Crystal Y Chen; Dan Huang; Shuyu Yao; Lisa Halliday; Gucheng Zeng; Richard C Wang; Zheng W Chen
Journal:  J Immunol       Date:  2012-04-02       Impact factor: 5.422

5.  Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies.

Authors:  Faiza Mougari; Feriel Bouziane; Flora Crockett; Rachid Nessar; Françoise Chau; Nicolas Veziris; Guillaume Sapriel; Laurent Raskine; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

6.  A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.

Authors:  Kevin A Nash; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

7.  Disseminated infection with Mycobacterium tilburgii in a male immunocompromised patient.

Authors:  Sarah Temmerman; Linos Vandekerckhove; Erica Sermijn; Dirk Vogelaers; Geert Claeys; Mario Vaneechoutte; Piet Cools; Steven Callens
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

8.  Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).

Authors:  Kevin A Nash
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  First Canadian Reports of Cervical Adenitis Due to Mycobacterium Malmoense and a 10-year Review of Nontuberculous Mycobacterial Adenitis.

Authors:  Chris McCrossin; Tim Mailman
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-03       Impact factor: 2.471

10.  Hernia repair mesh-associated Mycobacterium goodii infection.

Authors:  Muhammad R Sohail; Jerry D Smilack
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.